---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-077093"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2024-07-02T23:59:59+00:00"
generated_at: "2026-05-31T23:45:16.148343+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Buntanetap shows dose-dependent cognition gains; MDS-UPDRS improvements in PD Phase III

## Summary
- Buntanetap at 20mg significantly improved MDS-UPDRS Part II, III, II+III, and Total in PD patients diagnosed >3 years.
- In patients with mild dementia (MMSE 20-26), 20mg buntanetap showed significant cognitive improvement vs placebo.
- PIGD subgroup also showed significant motor and non-motor improvements with buntanetap.
- Safety profile consistent with prior AD data; no significant differences between early/advanced PD.
- FDA feedback led to primary endpoint change; primary and secondary endpoints met in specified subgroups.

## SEC filing metadata
- accession: 0001104659-24-077093
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2024-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465924077093/0001104659-24-077093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465924077093/tm2418712d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-077093
- JSON: https://secwatch.observer/filing/0001104659-24-077093.json
- Plain text: https://secwatch.observer/filing/0001104659-24-077093.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.